Research programme: antisense oligonucleotide based therapeutics- ProQR Therapeutics/Yarrow Biotechnology
Latest Information Update: 28 May 2023
At a glance
- Originator Yarrow Biotechnology
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 31 Dec 2022 ProQ Therapeutics has patent protections for Single-stranded rna-editing oligonucleotides in Japan, South Korea and the US
- 31 Dec 2022 ProQ Therapeutics has patents pending for Single-stranded rna-editing oligonucleotides in Australia, Canada, China, Eurasia, Europe, Israel, New Zealand, and the US (continuation application)
- 30 Sep 2022 Yarrow Therapeutics terminates its licence for ProQR Therapeutics’s antisense oligonucleotide technology